Global Cord Blood (CO) Competitors $1.55 -0.01 (-0.64%) As of 08/22/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsTrendsBuy This Stock CO vs. CORBF, MRAI, VMD, SMTI, NMRA, VOR, ALMS, VNDA, IMMP, and TKNOShould you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Global Cord Blood (CORBF), Marpai (MRAI), Viemed Healthcare (VMD), Sanara MedTech (SMTI), Neumora Therapeutics (NMRA), Vor Biopharma (VOR), Alumis (ALMS), Vanda Pharmaceuticals (VNDA), Prima BioMed (IMMP), and Alpha Teknova (TKNO). Global Cord Blood vs. Its Competitors Global Cord Blood Marpai Viemed Healthcare Sanara MedTech Neumora Therapeutics Vor Biopharma Alumis Vanda Pharmaceuticals Prima BioMed Alpha Teknova Global Cord Blood (NYSE:CORBF) and Global Cord Blood (NYSE:CO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Does the media prefer CORBF or CO? In the previous week, Global Cord Blood had 1 more articles in the media than Global Cord Blood. MarketBeat recorded 1 mentions for Global Cord Blood and 0 mentions for Global Cord Blood. Global Cord Blood's average media sentiment score of 1.11 beat Global Cord Blood's score of 0.00 indicating that Global Cord Blood is being referred to more favorably in the news media. Company Overall Sentiment Global Cord Blood Neutral Global Cord Blood Positive Which has preferable valuation & earnings, CORBF or CO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGlobal Cord Blood$196.12M0.96$79.04MN/AN/AGlobal Cord Blood$1.24B0.15$79.04M$0.642.42 Which has more risk and volatility, CORBF or CO? Global Cord Blood has a beta of -0.6, suggesting that its share price is 160% less volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Is CORBF or CO more profitable? Company Net Margins Return on Equity Return on Assets Global Cord BloodN/A N/A N/A Global Cord Blood N/A N/A N/A SummaryGlobal Cord Blood beats Global Cord Blood on 4 of the 5 factors compared between the two stocks. Get Global Cord Blood News Delivered to You Automatically Sign up to receive the latest news and ratings for CO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CO vs. The Competition Export to ExcelMetricGlobal Cord Bloodhealth & allied services, not elsewhere classified IndustryMedical SectorNYSE ExchangeMarket Cap$188.40M$133.49M$5.83B$21.32BDividend YieldN/AN/A4.40%3.51%P/E Ratio2.421.2122.8126.68Price / Sales0.150.60473.1755.22Price / Cash4.192.8038.0224.09Price / Book0.240.249.535.47Net Income$79.04M$43.11M$3.26B$992.74M7 Day PerformanceN/A119.59%2.14%2.68%1 Month Performance181.82%122.21%2.81%1.53%1 Year Performance53.47%102.11%30.70%10.77% Global Cord Blood Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGlobal Cord BloodN/A$1.55-0.6%N/A-10.9%$188.40M$1.24B2.421,202News CoveragePositive NewsCORBFGlobal Cord BloodN/A$1.25+127.3%N/A+53.5%$151.94M$196.12M0.001,200MRAIMarpaiN/A$1.42-1.4%N/A+199.4%$24.52M$34.87M-0.54150Gap DownVMDViemed Healthcare2.0404 of 5 stars$6.92+0.4%N/A+1.2%$267.23M$224.26M20.351,179SMTISanara MedTech2.06 of 5 stars$31.58+6.4%$50.00+58.3%+3.0%$264.22M$86.67M-27.2260News CoverageAnalyst RevisionNMRANeumora Therapeutics2.362 of 5 stars$1.64+0.6%$7.14+335.5%-85.9%$263.97MN/A-1.04108Positive NewsVORVor Biopharma1.9474 of 5 stars$2.04-4.7%$6.07+197.4%+135.9%$258.43MN/A-1.24140ALMSAlumis2.4434 of 5 stars$4.85+2.1%$20.17+315.8%-62.5%$258.43MN/A0.00N/AVNDAVanda Pharmaceuticals4.4049 of 5 stars$4.56+4.6%$16.50+261.8%-10.4%$257.63M$198.77M-4.04290Analyst ForecastIMMPPrima BioMed0.9953 of 5 stars$1.78+2.9%$7.00+293.3%-26.3%$253.94MN/A0.002,021Positive NewsUpcoming EarningsGap UpTKNOAlpha Teknova1.6899 of 5 stars$4.41-6.0%$10.00+126.8%-3.5%$250.99M$37.74M-10.50240 Related Companies and Tools Related Companies CORBF Competitors MRAI Competitors VMD Competitors SMTI Competitors NMRA Competitors VOR Competitors ALMS Competitors VNDA Competitors IMMP Competitors TKNO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CO) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global Cord Blood Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Global Cord Blood With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access